Leap Therapeutics Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Leap Therapeutics Inc Unternehmen

Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. It also has two preclinical antibody programs, FL-302 and FL-501. FL-302 is a Claudin18.2/CD137 (also known as 4-1BB) bispecific antibody that is in preclinical development. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.

Leap Therapeutics Inc Informationen



BörsenkürzelLPTX

Name des UnternehmensLeap Therapeutics Inc

IPO-datumJan 24, 2017

CEOMr. Douglas E. (Doug) Onsi

Anzahl der mitarbeiter52

WertpapierartOrdinary Share

GeschäftsjahresendeJan 24

Addresse47 Thorndike St, Suite B1-1

StadtCAMBRIDGE

BörseNASDAQ Capital Market Consolidated

LandUnited States of America

Postleitzahl02141

Telefon16177140360

Websitehttps://www.leaptx.com/

BörsenkürzelLPTX

IPO-datumJan 24, 2017

CEOMr. Douglas E. (Doug) Onsi

Führungskräfte von Leap Therapeutics Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Douglas E. (Doug) Onsi

President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director

140.87K

+30.09%

Dr. Christopher K. Mirabelli, Ph.D.

Chairman of the Board

23.05K

--

Ms. Christine Granfield

Vice President, Head - Regulatory Affairs and Quality

15.90K

--

Dr. Jason Baum, Ph.D.

Chief Scientific Officer

15.90K

--

Dr. James H. Cavanaugh, Ph.D.

Independent Director

214.00

--

Dr. Richard L. Schilsky, M.D.

Independent Director

--

Dr. Joseph Loscalzo, M.D., Ph.D.

Independent Director

--

Dr. William W. Li, M.D.

Independent Director

--

Mr. Christian M. Richard

Independent Director

--

Ms. Patricia (Patty) Martin

Independent Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Douglas E. (Doug) Onsi

President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director

140.87K

+30.09%

Dr. Christopher K. Mirabelli, Ph.D.

Chairman of the Board

23.05K

--

Ms. Christine Granfield

Vice President, Head - Regulatory Affairs and Quality

15.90K

--

Dr. Jason Baum, Ph.D.

Chief Scientific Officer

15.90K

--

Dr. James H. Cavanaugh, Ph.D.

Independent Director

214.00

--

Dr. Richard L. Schilsky, M.D.

Independent Director

--

Umsatzaufteilung

Keine Daten

Keine Daten

Nach Geschäftsbereich

Nach Region

Keine Daten

Aktionärsstatistik

Aktualisiert: Sat, Oct 18

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Winklevoss Capital Management, LLC

14.62%

Gilead Sciences Inc

9.39%

683 Capital Management LLC

2.55%

Acadian Asset Management LLC

2.18%

Beigene Ltd

2.15%

Andere

69.11%

Aktionäre

Anteil

Winklevoss Capital Management, LLC

14.62%

Gilead Sciences Inc

9.39%

683 Capital Management LLC

2.55%

Acadian Asset Management LLC

2.18%

Beigene Ltd

2.15%

Andere

69.11%

Aktionärstypen

Aktionäre

Anteil

Family Office

14.62%

Corporation

11.53%

Investment Advisor

8.64%

Investment Advisor/Hedge Fund

3.10%

Hedge Fund

2.85%

Venture Capital

1.26%

Individual Investor

0.42%

Research Firm

0.11%

Bank and Trust

0.01%

Andere

57.44%

Institutionelle Beteiligung



Aktualisiert: Sun, Oct 5

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q3

109

9.05M

16.44%

-10.74M

2025Q2

120

18.70M

45.12%

-8.55M

2025Q1

140

18.85M

45.62%

-6.95M

2024Q4

134

21.35M

55.72%

-2.16M

2024Q3

140

20.83M

54.42%

+2.16M

2024Q2

141

20.87M

54.74%

+4.28M

2024Q1

149

9.36M

39.74%

-1.79M

2023Q4

154

7.72M

34.00%

-3.79M

2023Q3

169

9.36M

44.45%

-1.96M

2023Q2

173

10.09M

52.77%

+1.83M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Gilead Sciences Inc

5.32M

12.84%

--

Jun 30, 2025

683 Capital Management LLC

1.44M

3.48%

-5.76K

-0.40%

Jun 30, 2025

Acadian Asset Management LLC

1.24M

2.99%

-43.42K

-3.39%

Jun 30, 2025

Beigene Ltd

1.22M

2.93%

+1.22M

--

Oct 31, 2024

The Vanguard Group, Inc.

1.16M

2.8%

-14.92K

-1.27%

Jun 30, 2025

Hightower Advisors, LLC

1.10M

2.65%

+1.05M

+2071.98%

Jun 30, 2025

Monaco asset management S.A.M.

1.05M

2.53%

--

Jun 30, 2025

Simplify Asset Management Inc

857.36K

2.07%

-93.61K

-9.84%

Jun 30, 2025

HealthCare Ventures LLC

697.23K

1.68%

+20.91K

+3.09%

Apr 21, 2025

Verbundene ETFs



Aktualisiert: Sun, Nov 2

Name

Anteil

Simplify Health Care ETF

0.35%

iShares Micro-Cap ETF

0%

Dimensional US Core Equity 1 ETF

0%

DFA Dimensional US Sustainability Core 1 ETF

0%

Avantis US Small Cap Equity ETF

0%

Simplify Health Care ETF

Anteil0.35%

iShares Micro-Cap ETF

Anteil0%

Dimensional US Core Equity 1 ETF

Anteil0%

DFA Dimensional US Sustainability Core 1 ETF

Anteil0%

Avantis US Small Cap Equity ETF

Anteil0%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Art

Verhältnis

Jun 20, 2023

Merger

10→1

Jun 20, 2023

Merger

10→1

Jun 20, 2023

Merger

10→1

Jun 20, 2023

Merger

10→1

Datum

Art

Verhältnis

Jun 20, 2023

Merger

10→1

Jun 20, 2023

Merger

10→1

Jun 20, 2023

Merger

10→1

Jun 20, 2023

Merger

10→1